MedTrace Logo

Glaucoma Adherence Study

NCT00676637 · Status: COMPLETED · Type: OBSERVATIONAL · Enrollment: 55

Last updated 2012-05-31

No results posted yet for this study

Summary

The purpose of this study is evaluate adherence to DuoTrav® when reinforced by the use of the Travalert™ Dosing Aid.

Conditions

Interventions

DRUG

Travoprost 0.004%/timolol 0.05% fixed combination eye drops (DuoTrav)

One drop in study eye(s) once daily in the evening for four months

DEVICE

Travalert Dosing Aid

Approved device used with DuoTrav and intended to provide an objective system for quantifying dosing and improving patient adherence

Sponsors & Collaborators

  • Alcon Research

    lead INDUSTRY

Principal Investigators

  • Anna Grau · Alcon Research

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2008-05-31
Primary Completion
2010-02-28
Completion
2010-02-28

Countries

  • France
  • Italy
  • Netherlands
  • United Kingdom

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00676637 on ClinicalTrials.gov